Do you have the same question? Follow this Question
May 22, 2025 - 09:48 AM
We’ve provided several answers to questions related to Atelvia (Risedronate) Delayed Release , see some other helpful Q&A related to this product.
Question: What precautions should be taken regarding dental work while on this medication?
Answer: Consult with your dentist and doctor about any planned dental work due to the risk of jaw bone problems. This precaution helps prevent osteonecrosis of the jaw, a serious condition associated with bisphosphonates.
Question: What is the ChEBI ID for this medication?
Answer: The ChEBI ID is 3666. The Chemical Entities of Biological Interest (ChEBI) database provides valuable information about the biological properties of chemical substances, aiding in research and development.
Question: What are some of the side effects of this medication?
Answer: Side effects may include diarrhea, flu-like symptoms, muscle pain, and pain in the back and joints. Recognizing these potential side effects helps users prepare and manage them, ensuring continued adherence to the treatment plan.
Question: What is the protein binding percentage of this medication?
Answer: The protein binding percentage is about 24%. This moderate level of protein binding affects how the drug is distributed and metabolized in the body, impacting its effectiveness and duration of action.
Question: What is the elimination half-life of this medication in the serum?
Answer: The elimination half-life in the serum is 1.5 hours. This indicates how long the medication stays active in the bloodstream, influencing how often it needs to be taken to maintain its effectiveness.
View all Atelvia (Risedronate) Delayed Release Questions & Answers
